Journal of Pioneering Medical Sciences
Received: February 18, 2026 | Accepted: April 15, 2026 | Published: June 05, 2026
Volume 15, Issue 05, Pages 79-83

DOI https://doi.org/10.47310/jpms2026150511

A New Player in the Game; Exploring the Prospective Role of Serotonin Dysfunction in Diabetic-Induced Depression: Preclinical and Clinical Evidence

Eslam Kamal Fahmy[1], Safya Ebraheem Esmaeel[2], Raghad Saad Alenezi[3], Basmah Dhiyab Alanazi[4], Watin Hamdan Alenezi[5], Dana Awad Alhazmi[6] and Baraah Abu Alsel[7]

[1,2]Department of Physiology, College of Medicine, Northern Border University (NBU), 91431, Arar, Saudi Arabia
[3-6]College of Medicine, Northern Border University (NBU), 91431, Arar, Saudi Arabia
[7]Medical Sciences and Preparatory Year Department, North Private College of Nursing, 73244, Arar, Saudi Arabia

Author Designation: [1,2,7]Assistant Professor, [3-6]Medical Student

*Corresponding author: Eslam Kamal Fahmy (e-mail: eslam.kamal.fahmy@gmail.com).

Abstract Diabetes mellitus and major depressive disorder frequently coexist, creating a bidirectional relationship that worsens clinical outcomes, glycemic control and quality of life. Emerging evidence suggests that serotonergic dysfunction may represent a key mechanistic link between metabolic dysregulation and mood disorders. This review explores the prospective role of serotonin (5-hydroxytryptamine, 5-HT) disturbances in the pathophysiology of diabetic-induced depression by integrating findings from both preclinical and clinical studies. Preclinical investigations using streptozotocin-induced, diet-induced and genetic models of diabetes consistently demonstrate alterations in central and peripheral serotonin levels, impaired tryptophan metabolism, changes in tryptophan hydroxylase and monoamine oxidase activity and regio-specific reductions of 5-HT within mood-regulating brain structures such as the hippocampus, cortex and hypothalamus. These neurochemical changes are frequently accompanied by depressive-like behaviors in validated behavioral paradigms. Additionally, diabetes is associated with modifications in serotonin transporter (SERT) function and altered expression of several serotonin receptor subtypes, including 5-HT1A and 5-HT2 receptors, suggesting disruption of serotonergic signaling pathways involved in emotional regulation and neuroplasticity. Clinical evidence further supports this relationship, indicating that diabetic patients often exhibit serotonergic abnormalities, inflammatory activation, insulin resistance-related neurotransmitter changes and gut-brain axis alterations that may contribute to depressive symptomatology. Therapeutically, selective serotonin reuptake inhibitors (SSRIs) and other serotonin-modulating strategies show potential benefits not only in alleviating depressive symptoms but also in influencing metabolic parameters. Collectively, the available evidence positions serotonin dysfunction as a promising mechanistic bridge between diabetes and depression. Understanding these interactions may open new avenues for integrated therapeutic strategies targeting both metabolic and neuropsychiatric components of diabetic-induced depression.

Key Words T2DM, Diabetic-Induced Depression, Major Depressive Disorder, Serotonin, SSRIs

INTRODUCTION

Major depressive disorder (MDD) and diabetes mellitus (both type 1 and type 2) co-occur at rates significantly higher than chance, which deteriorates the prognosis for both illnesses. People with diabetes have a higher prevalence and incidence of MDD, according to epidemiological studies and depression is associated with worse glycemic control, more complications and a higher death rate. Serotonin (5-hydroxytryptamine, 5-HT), a monoamine neurotransmitter essential to mood regulation and metabolic processes, is the subject of a significant neurochemical theory that links diabetes and depression. Chronic inflammation, altered synthesis, altered transporter/receptor expression/function, disrupted insulin-serotonin interactions and gut-derived serotonin changes can all lead to serotonergic dysfunction in diabetes; these alarms logically contribute to depressive symptomatology in diabetic patients [1] (Figure 1).

Preclinical Evidence

Serotonin Levels, Synthesis and Metabolism in Diabetic Models: Changes in cerebral and peripheral serotonin levels and enzymes that control 5-HT turnover are observed in



Figure 1: Serotonin as a Bridge between Diabetes and Depression

several rodent models of diabetes, including streptozotocin-induced type 1, high-fat diet/obesity-induced type 2 and genetic models. Reduced tryptophan hydroxylase activity, altered monoamine oxidase expression and decreased central 5-HT in the hippocampus, cortex and hypothalamus have all been reported in diabetic animals. These alterations are linked to depressive-like behaviors on common tests (forced swim, sucrose preference, novelty suppressed feeding). These results suggest that 5-HT bioavailability in brain areas related to mood regulation can be directly changed by diabetes [2].

Serotonin Transporter (SERT) and Receptor Alterations

Preclinical research indicates that diabetic animals have changed 5-HT receptor expression and compromised SERT function. While diabetes models often show downregulation of SERT and changes in 5-HT1A and 5-HT2 receptor expression in limbic regions, which may mediate depressive behaviors, SERT knockout or deficiency models reveal complex metabolic phenotypes, such as altered adiposity and glucose homeostasis, demonstrating bidirectional links between 5-HT handling and metabolism. The downstream plasticity and synaptic 5-HT dynamics are altered by these transporter and receptor alterations [3].

Neuroinflammation, Insulin Signaling and Serotonergic Neurons

Experimental diabetes affects central insulin signaling, which affects serotonergic neuron function and raises neuroinflammatory markers (proinflammatory cytokines, microglial activation). Insulin replacement or treatments that increase insulin sensitivity in diabetic rodents improve depressive-like behavior and restore aspects of 5-HT neurotransmission, indicating that insulin-serotonin cross-talk plays a functional role [4].

Behavioral Pharmacology: Serotonergic Agents in Diabetic Models

The results of studies that give diabetic animals serotonergic medications (SSRIs, selective 5-HT receptor agonists and intranasal serotonin) vary; some report improvements in metabolic parameters and depressive-like behaviors, while other studies show mixed or model-dependent results. In some rodent diabetes models, intranasal serotonin and selective 5-HT receptor agonists have been shown to enhance glucose regulation and mood-related behaviors, suggesting that 5-HT may have both metabolic and mood benefits. Sex, age and diet can all have moderating effects and not all models react in the same way [5].

Clinical Evidence

Epidemiology and Associations with Serotonergic Pharmacology: Clinical evidence indicates a strong correlation between depression and diabetes. While SSRIs and other antidepressants are widely effective for mood symptoms in diabetic patients, population studies have yielded conflicting results regarding whether certain antidepressants alter diabetes risk or metabolic control. These complex issues are further raised by observational analyses and pharmacoepidemiology studies. Pharmacovigilance datasets have suggested reporting signals for certain antidepressants, while other analyses (particularly for specific agents) indicate possible weight and metabolic effects, while other analyses show little net increased T2DM risk with SSRIs. Crucially, despite pharmacological complexity, treating depression frequently improves adherence and diabetes outcomes, highlighting clinical relevance [6].

Neurochemical and Imaging Studies in Humans

Supporting but inconsistent evidence is provided by human biochemical and imaging studies. Although results vary by methodology and patient population, studies of receptors, Positron Emission Tomography (PET) of SERT and cerebrospinal fluid (CSF) and plasma serotonin metabolites have demonstrated changes in serotonergic markers in subgroups of diabetic patients with depressive symptoms. Post-mortem and molecular research connect insulin signaling to serotonin metabolism, while some PET studies show decreased SERT availability in limbic regions among

depressed people. Compared to primary mood disorder research, the imaging literature in diabetes is more diverse and smaller, necessitating careful interpretation [7].

Genetic and Peripheral Markers (SERT Polymorphisms, Gut Serotonin)

Serotonin transporter gene (SLC6A4; 5-HTTLPR) and related serotonergic gene polymorphisms affect depression risk and seem to interact with metabolic phenotypes; some genotypes are associated with metabolic and gastrointestinal characteristics that are important for diabetes. In addition to influencing metabolic homeostasis, peripheral serotonin, which is primarily derived from the gut, may also serve as a mechanistic link between diabetes and mood through immune/gut-brain pathways. Modified peripheral 5-HT signaling has been linked to insulin secretion, hepatic glucose handling and adipose biology [8].

Clinical Trials: Antidepressant Efficacy in Patients with Diabetes

In diabetic patients, SSRIs and other antidepressants have been shown in Randomized Controlled Trials (RCTs) to improve depressive symptoms in most cases. There is also some evidence of modest benefits in glycemic control, which may be mediated by better adherence and lifestyle modifications. However, heterogeneity in trial design, small sample sizes and variable metabolic endpoints limit definitive conclusions about metabolic benefits or harms attributable directly to serotonergic mechanisms. Serotonergic antidepressants continue to be a standard treatment for depression in diabetics, although metabolic side-effect profiles should be taken into account when making a clinical decision [9].

Mechanistic Pathways Linking Diabetes, Serotonin Dysfunction and Depression

Insulin-Serotonin Interactions in the Brain: Insulin affects monoamine oxidase and serotonergic neuron signaling, which in turn affects monoamine metabolism, including 5-HT. As a result, brain insulin resistance, which is seen in some people with type 2 diabetes, can affect neurogenesis, synaptic plasticity and serotonergic neurotransmission-processes that are essential for mood regulation. By blocking MAO activity in animal models, experimental insulin administration can raise brain 5-HT, establishing a connection between serotonergic tone and metabolic regulation [10].

Neuroinflammation and Immune Modulation of 5-HT

Diabetes-related chronic low-grade inflammation changes the metabolism of tryptophan and kynurenine, lowers the availability of central serotonin precursors and modifies receptor expression. Indoleamine 2,3-dioxygenase (IDO) can be elevated by proinflammatory cytokines, diverting tryptophan from 5-HT synthesis in favor of kynurenine metabolites that may be neurotoxic or neuroactive, thus exacerbating depressive symptoms. SERT regulation and serotonergic neuron function are also impacted by neuroinflammation [11].

HPA Axis Dysregulation and Stress Response

Chronic glucocorticoid exposure can downregulate 5-HT1A receptors and impair serotonergic signaling and diabetes is linked to changes in stress response systems (HPA axis). Serotonergic dysfunction in diabetic depression may be caused by these HPA axis alterations as well as an effect of them [12].

Gut-Brain Axis and Peripheral Serotonin

Peripheral serotonin, which is mostly produced in the gut, influences immunological signaling, intestinal permeability and the metabolism of fats and carbohydrates. Changes in gut 5-HT signaling (caused by diet, microbiota and SERT genotype) can affect metabolic regulation and systemic inflammation. They can also alter vagal and endocrine signals to the brain, which can lead to mood dysregulation. This axis offers a believable explanation for the connection between depression, serotonergic dysregulation and diabetes [13].

Therapeutic Implications

Antidepressant Selection and Metabolic Considerations: SSRI antidepressants are still useful for treating depression in diabetic patients but when selecting a treatment plan, doctors should take the agent's unique metabolic profile (weight gain, glycemic effects) into account. Although there is no proof that all SSRIs increase the risk of type 2 diabetes, it is advised to be on the lookout for metabolic side effects. Depression treatment frequently enhances diabetes self-management and may result in mild glycemic improvements [14].

Targeting Serotonergic Pathways for Combined Metabolic and Mood Benefit

The potential for treatments that address both metabolic dysfunction and mood symptoms is increased by preclinical data supporting intranasal serotonin, selective 5-HT receptor agonists or combined GLP-1/serotonin pathway modulation. According to early translational research, dual-action strategies (such as medications that improve insulin sensitivity while favorably modulating central 5-HT) should be tested in clinical settings. Given the intricate peripheral effects of 5-HT on appetite, glucose metabolism and cardiovascular function, caution is necessary [15].

Non-Pharmacological Strategies Affecting Serotonin and Metabolic Health

Glycemic control and serotonergic function (e.g., through tryptophan availability and neuroplasticity) are positively impacted by lifestyle interventions (diet, exercise and sleep optimization). Weight loss and physical exercise are two examples of interventions that lower inflammation and

increase insulin sensitivity. These interventions may also indirectly restore serotonergic tone and lessen depressive symptoms in diabetic patients [16].

Limitations of Current Evidence

Translational gaps persist despite convergent preclinical findings and mechanistic credibility. There are comparatively few and varied human studies that measure central serotonin function directly in diabetic populations. Confounding (such as antidepressant selection bias and lifestyle differences) makes it difficult to draw conclusions about causality and many clinical trials are underpowered for metabolic endpoints. Although the contributions of the microbiome and genes are encouraging, larger, carefully monitored cohort studies are needed. Inconsistent results across studies are also caused by variations in rodent models' diet, sex distribution and disease induction (type 1 vs. type 2 features) [17].

Future Directions

- **Longitudinal Human Studies:** Combining PET imaging of SERT/receptors, CSF metabolite measures and detailed metabolic phenotyping to track how changes in insulin sensitivity and inflammation predict serotonergic alterations and depressive symptoms [7]
- **Interventional Trials:** Testing agents that target both serotonergic and metabolic pathways (e.g., selective receptor modulators, combination GLP-1/5-HT strategies), with prespecified mood and metabolic endpoints [15]
- **Integrative Gut-Brain Research:** Exploring how SERT polymorphisms, microbiome composition and diet influence peripheral and central serotonin, inflammation and mood in diabetes [8]
- **Personalized Medicine Approaches:** Leveraging genotyping (e.g., 5-HTTLPR), metabolomics and imaging to tailor antidepressant and metabolic treatments in diabetic patients with depression [17]

CONCLUSIONS

The serotonergic system is a key mechanistic link in diabetic depression, with its function compromised by the inflammatory and metabolic sequelae of diabetes. Consequently, evidences support the therapeutic rationale for using selective serotonin reuptake inhibitors (SSRIs), which not only treat depressive symptoms but may also offer modest benefits to glycemic control. Future research should target upstream mechanisms, such as neuroinflammation and the indoleamine 2,3-dioxygenase (IDO) pathway, as therapeutic strategies.

Serotonergic dysfunction in diabetes is driven by a complex interplay of several pathways, including brain insulin resistance, hypothalamic- pituitary-adrenal (HPA) axis dysregulation and disruptions in the gut- brain axis. Crucially, diabetes-associated chronic neuroinflammation elevates indoleamine 2,3-dioxygenase (IDO) activity, which diverts tryptophan away from serotonin synthesis and exacerbates depressive symptoms. Conclusion: The serotonergic system represents a key bridge in the pathophysiology of diabetic-induced depression. While current SSRI treatments offer therapeutic rationale and symptomatic relief, future research must prioritize dual-action strategies and upstream targets-such as neuroinflammation and the IDO pathway-to simultaneously address metabolic dysfunction and mood disorders.

REFERENCES

[1] Prabhakar, V. *et al.* "Diabetes-Associated Depression: The Serotonergic System as a Novel Multifunctional Target." *Indian Journal of Pharmacology*, vol. 47, no. 1, 2015, pp. 4-10. https://doi.org/10.4103/0253-7613.150305.

[2] Palazzo, E. *et al.* "Affective and Cognitive Impairments in Rodent Models of Diabetes." *Current Neuropharmacology*, vol. 22, no. 8, 2024, pp. 1327-1343. https://doi.org/10.2174/1570159X22666240124164804.

[3] Homberg, J.R. *et al.* "Serotonin Transporter Deficiency Increases Abdominal Fat in Female, but Not Male Rats." *Obesity*, vol. 18, no. 1, 2010, pp. 137-145. https://doi.org/10.1038/oby.2009.139.

[4] Khawagi, W.Y. *et al.* "Depression and Type 2 Diabetes: A Causal Relationship and Mechanistic Pathway." *Diabetes, Obesity & Metabolism*, vol. 26, no. 8, 2024, pp. 3031-3044. https://doi.org/10.1111/dom.15630.

[5] Derkach, K.V. *et al.* "The Effect of Long-Term Intranasal Serotonin Treatment on Metabolic Parameters and Hormonal Signaling in Rats with High-Fat Diet/Low-Dose Streptozotocin-Induced Type 2 Diabetes." *International Journal of Endocrinology*, vol. 2015, 2015. https://doi.org/10.1155/2015/245459.

[6] Kuo, H.Y. *et al.* "Antidepressants and Risk of Type 2 Diabetes Mellitus: A Population-Based Nested Case-Control Study." *Journal of Clinical Psychopharmacology*, vol. 40, no. 4, 2020, pp. 359-365. https://doi.org/10.1097/JCP.0000000000001 228.

[7] Anthony, D.C. *et al.* "Impact of Serotonin Transporter Absence on Brain Insulin Receptor Expression, Plasma Metabolome Changes and ADHD-like Behavior in Mice Fed a Western Diet." *Biomolecules*, vol. 14, no. 8, 2024. https://doi.org/10.3390/biom14080884.

[8] Malik, A. *et al.* "Impact of Serotonin Transporter Gene Polymorphism on Gut Motility in Patients with Type 2 Diabetes Mellitus." *Journal of Neurogastroenterology and Motility*, vol. 27, no. 2, 2021, pp. 240-247.

[9] Alruwaili, N.S. *et al.* "Antidepressants and Type 2 Diabetes: Highways to Knowns and Unknowns." *Diabetology & Metabolic Syndrome*, vol. 15, no. 1, 2023. https://doi.org/10.1186/s13098-023-01149-z.

[10] Yoo, Y.M. and S.S. Joo. "Serotonin Influences Insulin Secretion in Rat Insulinoma INS-1E Cells." *International Journal of Molecular Sciences*, vol. 25, no. 13, 2024. https://doi.org/10.3390/ijms25136828.

[11] Pomytkin, I.A. *et al.* "Endotoxaemia Resulting from Decreased Serotonin Transporter (5-HTT) Function: A Reciprocal Risk Factor for Depression and Insulin Resistance?" *Behavioural Brain Research*, vol. 276, 2015, pp. 111-117. https://doi.org/10.1016/j.bbr.2014.04.049.

[12] Rowland, N.E. and L.L. Bellush. "Diabetes Mellitus: Stress, Neurochemistry and Behavior." *Neuroscience and Biobehavioral Reviews*, vol. 13, no. 4, 1989, pp. 199-206. https://doi.org/10.1016/S0149-7634(89)80054-5.

[13] Calzadilla, N. *et al.* "Serotonin Transporter Deficiency Induces Metabolic Alterations in the Ileal Mucosa." *International Journal of Molecular Sciences*, vol. 25, no. 8, 2024. https://doi.org/10.3390/ijms25084459.

[14] Siafis, S. and G. Papazisis. "Detecting a Potential Safety Signal of Antidepressants and Type 2 Diabetes: A Pharmacovigilance-Pharmacodynamic Study." *British Journal of Clinical Pharmacology*, vol. 84, no. 10, 2018, pp. 2405-2414. https://doi.org/10.1111/bcp.13699.

[15] Kolling, L.J. *et al.* "Interaction of Serotonin/GLP-1 Circuitry in a Dual Preclinical Model for Psychiatric Disorders and Metabolic Dysfunction." *Psychiatry Research*, vol. 337, 2024. https://doi.org/10.1016/j.psychres.2024.115951.

[16] Fanelli, G. *et al.* "The Interface of Depression and Diabetes: Treatment Considerations." *Translational Psychiatry*, vol. 15, no. 1, 2025. https://doi.org/10.1038/s41398-025-03234-5.

[17] Veniaminova, E. *et al.* "Metabolic, Molecular and Behavioral Effects of Western Diet in Serotonin Transporter-Deficient Mice: Rescue by Heterozygosity?" *Frontiers in Neuroscience*, vol. 14, 2020. https://doi.org/10.3389/fnins.2020.00024.